IART
Integra LifeSciences Holdings
Integra LifeSciences Holdings historical holders
total: 1
Olstein Capital Management Integra LifeSciences Holdings transactions over time
- Total transactions:
- 31
- New positions:
- 2
- Sold out:
- 2
- Added:
- 20
- Reduced:
- 7
- Held since:
- 2019 Q2
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
Robert Olstein has been an institutional investor in Integra LifeSciences Holdings (IART) since 2014 Q1. According to 2026 Q2 report, Robert Olstein doesn't hold any shares. The fund/company first acquired IART in 2014 Q1, initially purchasing 98,000 shares. Robert Olstein later completely sold out the position and reinvested in IART again in 2019 Q2. Since the initial investment, Olstein Capital Management has made 30 more transactions in this position.
When did Robert Olstein exit their IART position?
Robert Olstein no longer holds Integra LifeSciences Holdings (IART). They sold off their entire position in 2026 Q1, closing out an investment that began in 2014 Q1.
When did Robert Olstein first invest in IART?
Robert Olstein first invested in Integra LifeSciences Holdings (IART) in 2014 Q1 at the reported quarter-end price of $23.00 per share, acquiring 98,000 shares in their initial purchase.
What is Robert Olstein's average cost basis for IART?
Based on historical transaction data, Robert Olstein's estimated cost basis for Integra LifeSciences Holdings (IART) is approximately $32.45 per share. This represents their average reported price* across all buy transactions.
Has Robert Olstein reinvested in IART after selling?
Yes, Robert Olstein has shown renewed interest in Integra LifeSciences Holdings (IART). After completely selling their position, they reinitiated an investment in 2019 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $32.45
- Weighted AVG sell price:
- $17.50
IART transactions history by Olstein Capital Management
31 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$12.42
|
|
-100% (-123,000)
|
-0.31%
|
|
2025 Q4
|
0.31%
|
123,000
|
$12.42
|
$1,528,000
|
-11.51% (-16,000)
|
-0.04%
|
|
2025 Q3
|
0.38%
|
139,000
|
$14.33
|
$1,992,000
|
+2.96% (+4,000)
|
+0.01%
|
|
2025 Q2
|
0.31%
|
135,000
|
$12.27
|
$1,656,000
|
+37.76% (+37,000)
|
+0.09%
|
|
2025 Q1
|
0.40%
|
98,000
|
$21.99
|
$2,155,000
|
-26.32% (-35,000)
|
-0.14%
|
|
2024 Q4
|
0.53%
|
133,000
|
$22.68
|
$3,016,000
|
-14.19% (-22,000)
|
-0.08%
|
|
2024 Q3
|
0.48%
|
155,000
|
$18.17
|
$2,816,000
|
+37.17% (+42,000)
|
+0.13%
|
|
2024 Q2
|
0.59%
|
113,000
|
$29.14
|
$3,293,000
|
+13.00% (+13,000)
|
+0.07%
|
|
2024 Q1
|
0.58%
|
100,000
|
$35.45
|
$3,545,000
|
+35.14% (+26,000)
|
+0.15%
|
|
2023 Q4
|
0.54%
|
74,000
|
$43.55
|
$3,223,000
|
+4.23% (+3,000)
|
+0.02%
|
|
2023 Q3
|
0.46%
|
$38.18
|
+2.90% (+2,000)
|
|||
|
2023 Q2
|
0.46%
|
$41.13
|
+53.33% (+24,000)
|
|||
|
2023 Q1
|
0.40%
|
$57.40
|
-2.17% (-1,000)
|
|||
|
2022 Q3
|
0.33%
|
$42.37
|
+2.22% (+1,000)
|
|||
|
2022 Q2
|
0.36%
|
$54.02
|
+7.14% (+3,000)
|
|||
|
2022 Q1
|
0.34%
|
$64.26
|
-6.67% (-3,000)
|
|||
|
2021 Q4
|
0.36%
|
$67.00
|
+9.76% (+4,000)
|
|||
|
2021 Q3
|
0.34%
|
$68.49
|
-10.87% (-5,000)
|
|||
|
2020 Q4
|
0.48%
|
$64.91
|
+6.98% (+3,000)
|
|||
|
2020 Q3
|
0.37%
|
$47.21
|
+19.44% (+7,000)
|
|||
|
2020 Q2
|
0.32%
|
$47.00
|
+13.53% (+4,290)
|
|||
|
2020 Q1
|
0.31%
|
$44.65
|
+51.00% (+10,710)
|
|||
|
2019 Q4
|
0.19%
|
$58.29
|
+133.33% (+12,000)
|
|||
|
2019 Q3
|
0.08%
|
$60.11
|
+12.50% (+1,000)
|
|||
|
2019 Q2
|
0.07%
|
$55.88
|
new
|
|||
|
2015 Q3
|
0.00%
|
$33.68
|
-100% (-116,000)
|
|||
|
2015 Q2
|
0.41%
|
$33.68
|
-3.33% (-4,000)
|
|||
|
2015 Q1
|
0.40%
|
$30.82
|
+5.26% (+6,000)
|
|||
|
2014 Q4
|
0.38%
|
$27.11
|
+3.64% (+4,000)
|
|||
|
2014 Q2
|
0.35%
|
$23.53
|
+12.24% (+12,000)
|
|||
|
2014 Q1
|
0.31%
|
$23.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.